Logotype for Acme United Corporation

Acme United (ACU) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Acme United Corporation

Q3 2026 earnings summary

10 Nov, 2026

Executive summary

  • Q3 2026 net sales were $58.013m, up 18% YoY; excluding My Medic, sales increased 10%.

  • Net income rose 80% to $3.435m, or $0.80 diluted EPS; excluding the net after-tax tariff-refund benefit, net income was $2.4m, up 24%.

  • Results reflected broad-based sales growth, a $4.0m tariff-refund gain, and $1.8m of DMT closure charges.

Financial highlights

  • Q3 gross profit was $26.300m versus $19.195m; gross margin was 45.3% versus 39.1%.

  • Q3 operating income was $4.463m versus $3.007m; net income was $3.435m versus $1.903m.

  • 9M net sales increased 16% to $173.030m; growth excluding My Medic was 8%. Net income was $9.469m versus $8.308m, and diluted EPS was $2.29 versus $2.03.

  • 9M operating income was $13.037m versus $11.824m; operating cash flow was $10.921m.

  • Q3 SG&A was $21.8m, or 37.6% of sales, versus $16.2m, or 32%; 9M SG&A was $60.7m, or 35%, versus $47.5m, or 32%.

Outlook and guidance

  • Q4 is expected to be seasonally strong in sales and earnings, including internationally; My Medic has historically generated most of its profit in Q4.

  • DMT closure savings are expected to exceed $1.0m annually beginning in 2027.

  • My Medic retail and distribution commitments for 2027 are beginning to come in; First Aid business is booked for 2027, with integration progressing on plan.

  • Strategic acquisitions remain under evaluation; management expects another deal may occur within 12 months while remaining selective and avoiding high leverage.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Acme United